New Meta-Analysis Maps the Effects of a 5 mg THC Dose

Bottom line: researchers combined 41 randomized, double-blind, placebo-controlled THC experiments involving 1,020 healthy people who used cannabis infrequently. Compared with placebo, THC increased feeling high, anxiety and tiredness while reducing alertness. Their model estimated that 5 mg of inhaled THC produced a substantial subjective response, but the result should not be treated as a universal serving recommendation.

What the Review Measured

The September 2026 review in Neuroscience & Biobehavioral Reviews included randomized experiments in which participants received THC and placebo under blinded conditions. The 1,020 participants were healthy and used cannabis less than twice weekly and fewer than 100 times in their lives.

The researchers converted different study rating scales to a common 100-point scale and compared peak acute effects. Across the pooled studies, THC increased ratings of feeling high, anxiety and tiredness, reduced alertness and contentedness, and did not produce a statistically clear overall change in calmness.

Those are group averages. They do not describe every participant, and they do not show how a specific gummy, flower, vape or beverage will affect a particular consumer. Product composition, inhalation technique, metabolism, setting and prior exposure all change the experience. Our delta-9 THC explainer covers those variables in plain language.

What the 5 mg Estimate Actually Says

For 5 mg of inhaled THC, the model estimated an average increase of 34.3 points in feeling high, 14.4 points in anxiety and 26.3 points in tiredness on 100-point scales. Alertness fell by an estimated 40.2 points. The calmness estimate rose 4.5 points, but its confidence interval crossed zero, which means the data did not establish a clear change.

The authors also found that greater inhaled THC dose was associated with a stronger feeling of being high and lower calmness. They did not find a statistically clear inhaled dose relationship for anxiety, tiredness or alertness, even though THC and placebo differed on those outcomes overall. That distinction matters: a drug can produce an effect without the available studies establishing a smooth, predictable dose slope for that effect.

Five milligrams is also a research-reporting unit. A joint NIH notice defines one standard THC unit as 5 mg so studies can describe exposure more consistently. The agency explicitly says the unit is not meant to prescribe an allowable quantity. It is not a federal safety threshold, consumer serving recommendation or promise of mild effects.

Why Inhaled and Oral THC Cannot Be Read the Same Way

The review separated inhaled and oral administration. Its oral meta-regression did not find a statistically significant relationship between dose and the subjective outcomes. That result should not be interpreted to mean edible effects are dose-independent.

Oral THC is absorbed and metabolized differently, and study timing can miss or blur its delayed peak. A separate controlled study of 17 infrequent users found that 10, 25 and 50 mg oral THC produced dose-related changes. Effects began 30 to 60 minutes after ingestion and peaked 1.5 to 3 hours later. The higher doses produced pronounced subjective effects and cognitive and psychomotor impairment.

Another double-blind study of 20 infrequent users directly compared oral and vaporized THC. Low doses of 10 mg oral or 5 mg vaporized THC produced subjective effects without statistically significant impairment on the study's performance tests, while 25 mg oral and 20 mg vaporized THC impaired performance. A negative test result at a low dose is not proof that someone is safe to drive.

Who the Estimate Does Not Represent

The review focused on healthy adults with infrequent use. It does not establish the same response in daily consumers with tolerance, adolescents, older adults, pregnant people, medical-cannabis patients or people with cardiovascular or psychiatric conditions. It also does not measure long-term benefit or harm.

Tolerance is especially important. Frequent exposure can reduce how strongly some effects are felt, but feeling accustomed to THC does not guarantee that attention, reaction time or judgment are unimpaired. CannaWize's CB1 tolerance report explains the emerging biology, while the driving evidence review separates subjective intoxication from road safety.

CBD Is Not a Reliable Off Switch

Some products imply that CBD automatically softens THC's unwanted effects. A separate randomized crossover trial tested 10 mg of vaporized THC with 0, 10, 20 or 30 mg of CBD in 46 healthy infrequent users. THC impaired delayed verbal recall and increased measured psychotic symptoms, and none of the tested CBD doses significantly reduced the acute effects.

That study does not prove CBD never changes a THC experience. It does show that a CBD:THC ratio on a label is not a dependable guarantee against acute impairment or anxiety. Consumers should be skeptical of products marketed as self-correcting simply because they contain both cannabinoids.

Practical Implications for Consumers

The most useful public-health message is that 5 mg of THC can be clearly intoxicating for an infrequent user. It should not be dismissed as too small to matter. Inhaled products can act quickly, while edibles may take much longer to peak, which makes rapid redosing particularly risky. The edible safety guide explains why delayed onset and serving confusion can turn a planned dose into a much larger one.

Do not drive or operate machinery after using intoxicating cannabis. Keep THC products secured from children and pets, read the entire label rather than only the front-panel number, and avoid assuming that an advertised milligram amount equals the dose actually delivered to the bloodstream.

For Texas readers, scientific dose units do not change product legality. State and federal hemp rules use statutory definitions, laboratory measures and product restrictions that are separate from research standards. Our Texas THCA legal guide tracks that distinction and links to current official sources.

What Researchers Still Need to Resolve

The meta-analysis improves the shared map of acute THC effects, but it also exposes gaps. More standardized studies are needed for oral products, experienced consumers, medical populations, sex and age differences, and products with other cannabinoids and terpenes. Researchers also need better agreement on how rating scales are worded and when peak effects are measured.

For now, the evidence supports a precise conclusion: one 5 mg research unit of inhaled THC produced a clear average subjective response in healthy infrequent users. It does not tell every consumer exactly how they will feel, and it should not be converted into a universal safe dose.